Core Viewpoint - Agomab Therapeutics NV has successfully completed its initial public offering, raising approximately $200 million to support its development of novel therapies for immunology and inflammatory diseases, particularly chronic fibrotic conditions with high unmet medical needs [1][6]. Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on creating disease-modifying therapies for immunology and inflammatory diseases, with an emphasis on chronic fibrotic indications [1][6]. - The company's product candidates aim to target established pathways and utilize validated modalities to enhance efficacy while minimizing systemic toxicities, addressing limitations of previous therapeutic approaches [6]. Financial Details - The initial public offering consisted of 12,500,000 American Depositary Shares (ADSs) priced at $16.00 per ADS, resulting in gross proceeds of approximately $200 million before expenses [1][2]. - The ADSs began trading on the Nasdaq Global Select Market under the ticker symbol "AGMB" on February 6, 2026 [2]. Offering Management - J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen served as joint book-running managers for the offering [2].
Agomab Announces Closing of Initial Public Offering